Breaking News: SciTech has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Health & Human Services (HHS) for the use of its lead drug product ST-001 nanoFenretinide in the treatment of patients infected with COVID-19 (SARS-CoV-2).

SCITECH at a glance

Drug Product

ST-001 nanoFenretinide (Proprietary Formulation)
= Fenretinide + SDV.


Drug Target

2 cancer indications: t-cell lymphoma; and,
small cell lung cancer (SCLC);
All diseases with limited therapeutic options.


Proven Anti-Cancer Drug
Fenretinide has established efficacy in humans;
shown to be safe in 1,000’s of patients.


Unique ST-001 nanoFenretinide Formulation
Drug delivery of therapeutic doses - safely & effectively.


Strategic & Rapid Drug Development
Existing human efficacy data;
Access to NCI data;
Streamlined clinical trials design;
Fenretinide provided free by NCI.

FDA expedited programs anticipated:
(1) Fast Track designation
(2) FDA Orphan Drug designation - Granted Dec. 2017
(3) Accelerated Approval pathway
(4) Priority Review designation.


Amount of Financing Sought
$15MM Series A for completion of clinical trials required for NDA filing.


Use of Funds
cGMP drug manufacture (ST-001) Clinical Trials (Phase I);
FDA compassionate use approval & NDA filings.


Exit Strategy
Targeted acquisition.


Time to Market
2-3 years (unusually short).

Drug Mechanism of Action (MOA)

ST-001 NanoFenretinde Drug MOA (YouTube video)



Twitter - #SciTechUSA - SciTech Develop
Pinterest - SciTech Development

For investment and partnering opportunities contact:

Earle Holsapple  | 

© 2017-2020 SciTech Development LLC